China Isotope & Radiation Corporation logo

China Isotope & Radiation Corporation

1763.HK

HKSEHealthcareMedical - Devices

Latest quote

HK$17.00

+HK$0.34 · +2.04%

Aug 24, 4:08 PM HKT

1763.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Junqi Zhang
Listed since
Jul 6, 2018
Employees
3,578

Market position

Day range

Current HK$17.00

52-week range

Current HK$17.00

Open
HK$16.66
Previous close
HK$16.66
Volume
4.6K
0.04× average
Average volume
114.69K
Average daily volume
Market cap
5.44B HKD
Beta
0.48
Market reference 1
50-day average
HK$17.2944
-1.70% below average
200-day average
HK$19.7254
-13.82% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.94B CNY
P/E (TTM)
14.58×
P/B (TTM)
0.89×
P/S (TTM)
0.67×
EV / EBITDA
5.08×
Earnings yield
5.50%
Free cash flow yield
-0.83%
Dividend yield
2.05%

Profitability & efficiency

Gross margin
50.31%
Operating margin
13.09%
Net margin
4.56%
Return on equity
6.10%
Return on assets
2.03%
Return on invested capital
5.34%

Financial health

Debt / equity
0.52×
Current ratio
1.76×
Altman Z-score
2.23
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends69%45%22%-1%Gross margin, FY2021: 63.03%Gross margin, FY2022: 57.18%Gross margin, FY2023: 52.48%Gross margin, FY2024: 48.62%Gross margin, FY2025: 50.31%Operating margin, FY2021: 15.12%Operating margin, FY2022: 14.87%Operating margin, FY2023: 14.19%Operating margin, FY2024: 14.34%Operating margin, FY2025: 13.09%Net margin, FY2021: 6.53%Net margin, FY2022: 6.38%Net margin, FY2023: 5.59%Net margin, FY2024: 5.37%Net margin, FY2025: 4.56%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.03%. Gross margin FY2022 57.18%. Gross margin FY2023 52.48%. Gross margin FY2024 48.62%. Gross margin FY2025 50.31%. Operating margin FY2021 15.12%. Operating margin FY2022 14.87%. Operating margin FY2023 14.19%. Operating margin FY2024 14.34%. Operating margin FY2025 13.09%. Net margin FY2021 6.53%. Net margin FY2022 6.38%. Net margin FY2023 5.59%. Net margin FY2024 5.37%. Net margin FY2025 4.56%.

Income trends

Revenue

7B CNY-7.57%

Operating income

916.2M CNY-15.66%

Net income

318.95M CNY-21.57%
Income trends across reported periods8.3B CNY5.4B CNY2.5B CNY−406.63M CNYRevenue, FY2021: 5.14B CNYRevenue, FY2022: 6.15B CNYRevenue, FY2023: 6.63B CNYRevenue, FY2024: 7.57B CNYRevenue, FY2025: 7B CNYOperating income, FY2021: 777.82M CNYOperating income, FY2022: 913.96M CNYOperating income, FY2023: 941.6M CNYOperating income, FY2024: 1.09B CNYOperating income, FY2025: 916.2M CNYNet income, FY2021: 335.75M CNYNet income, FY2022: 392.28M CNYNet income, FY2023: 370.97M CNYNet income, FY2024: 406.65M CNYNet income, FY2025: 318.95M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.14B CNY. Revenue FY2022 6.15B CNY. Revenue FY2023 6.63B CNY. Revenue FY2024 7.57B CNY. Revenue FY2025 7B CNY. Operating income FY2021 777.82M CNY. Operating income FY2022 913.96M CNY. Operating income FY2023 941.6M CNY. Operating income FY2024 1.09B CNY. Operating income FY2025 916.2M CNY. Net income FY2021 335.75M CNY. Net income FY2022 392.28M CNY. Net income FY2023 370.97M CNY. Net income FY2024 406.65M CNY. Net income FY2025 318.95M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue7B CNY7.57B CNY6.63B CNY6.15B CNY5.14B CNY
Cost of goods sold3.48B CNY3.89B CNY3.15B CNY2.63B CNY1.9B CNY
Gross profit3.52B CNY3.68B CNY3.48B CNY3.51B CNY3.24B CNY
Research and development294.1M CNY300.29M CNY306.05M CNY300.51M CNY196.21M CNY
Selling, general, and administrative2.33B CNY2.33B CNY2.4B CNY2.36B CNY2.32B CNY
Operating expenses2.61B CNY2.6B CNY2.54B CNY2.61B CNY2.46B CNY
Interest income16.85M CNY29.62M CNY30.97M CNY45.29M CNY26.25M CNY
Interest expense69.18M CNY48.42M CNY36.14M CNY35.34M CNY35.8M CNY
Depreciation and amortization252.98M CNY223.23M CNY264.35M CNY182.76M CNY158.58M CNY
Operating income916.2M CNY1.09B CNY941.6M CNY913.96M CNY777.82M CNY
Net income318.95M CNY406.65M CNY370.97M CNY392.28M CNY335.75M CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 5 misses, 0 met estimates
Average EPS surprise
-55.37%
5 comparable reports
Latest EPS result
0.51

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.731.270.80.34Q3 '22MissQ2 '23MissQ3 '23No estimateQ1 '24No estimateQ3 '24No estimateQ1 '25No estimateQ3 '25No estimateQ1 '26No estimate
Q3 2022, reported Aug 31, 2022: actual 0.398, estimate 1.63, surprise -75.57%, Miss. Q2 2023, reported Apr 26, 2023: actual 1, estimate 1.63, surprise -38.65%, Miss. Q3 2023, reported Aug 29, 2023: actual 0.431, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual 0.841, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual 0.515, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 0.84, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual 0.591, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual 0.512, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.27B4.43B3.59B2.75BQ3 '22MissQ2 '23BeatQ3 '23MissQ1 '24BeatQ3 '24No estimateQ1 '25No estimateQ3 '25No estimateQ1 '26No estimate
Q3 2022, reported Aug 31, 2022: actual 2.98B HKD, estimate 3.6B HKD, surprise -17.18%, Miss. Q2 2023, reported Apr 26, 2023: actual 4.02B HKD, estimate 3.6B HKD, surprise +11.86%, Beat. Q3 2023, reported Aug 29, 2023: actual 2.95B HKD, estimate 3.6B HKD, surprise -18.04%, Miss. Q1 2024, reported Mar 27, 2024: actual 4.31B HKD, estimate 3.6B HKD, surprise +19.79%, Beat. Q3 2024, reported Aug 30, 2024: actual 3.02B HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 5.07B HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual 3.13B HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual 4.61B HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.4254

2025 complete year+95.9% since 2021

2026 partial: HK$0.2604

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 23, 2026

HK$0.2604

Irregular

Record Jun 24, 2026 · Payment Aug 17, 2026

Dividend

Ex-dividend Oct 21, 2025

HK$0.0884

Monthly

Record Oct 22, 2025 · Payment Dec 31, 2025

Dividend

Ex-dividend Jun 5, 2025

HK$0.337

Semi-Annual

Record Jun 6, 2025 · Payment Aug 1, 2025

Dividend

Ex-dividend Sep 27, 2024

HK$0.0799

Semi-Annual

Record Sep 30, 2024 · Payment Nov 22, 2024

Dividend

Ex-dividend Jun 19, 2024

HK$0.3438

Irregular

Record Jun 20, 2024 · Payment Aug 13, 2024

Dividend

Ex-dividend Jul 4, 2023

HK$0.4785

Annual

Record Jul 5, 2023 · Payment Aug 31, 2023

1763.HK peers

ETFs holding 1763.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 1763.HK

research.disclaimer